Newsroom

The first edition of the advanced in vivo calcium imaging workshop using Miniscopes took place at the Institute from June 10 to 12. This intensive course, organized by AnderoLab, equipped participants with essential skills to study neuronal activity in freely moving rodents.

A study by the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) reveals that inflammation associated with Marfan syndrome increases vulnerability to neurological diseases and complications following strokes, as demonstrated in animal models.

An international study led by the Institut de Neurociències at the UAB (INc-UAB) has shown that increasing levels of the Klotho protein in mice extends lifespan and improves both physical and cognitive health when aging.

A collaborative study involving the Universitat Autònoma de Barcelona (UAB) has shown that the molecule MP-010 can enhance motor function and extend lifespan in a mouse model of Amyotrophic Lateral Sclerosis (ALS), a severe neurodegenerative disease for which there are currently no effective treatments.

According to a study led by Dr. Raül Andero, the drug Osanetant could reduce the intensity at which the fear memory is consolidated, thus preventing the onset of post-traumatic stress disorder (PTSD). The research, conducted with female mice, highlights important sex differences in fear processing.

A recent study led by Dr Assumpció Bosch demonstrates the potential of gene therapy to restore motor capacity in an ultra-rare disease, Megalencephalic Leukoencephalopathy with Subcortical Cysts (MLC), even when treatment begins after symptom onset.

The event brought together 40 renowned researchers to advance science in Spain and foster collaborations.

On February 20th, 2025 took place the official launch of the DIPOLE project, a collaborative initiative aimed at advancing personalized treatment for pharmacoresistant epilepsies. 

Professor Raul Andero’s laboratory, Translational Mechanisms of Fear Memory, has registered a European patent on the use of Fezolinetant—a drug originally developed to treat vasomotor symptoms associated with menopause—for modulating the consolidation of aversive memories.

Seventeen female researchers from the Institute have been recognized in the recent "Ranking of Spanish Women Researchers" published this February.